Brief: FDA Removes Partial Clinical Hold On TuHURA Biosciences' Phase 3 Accelerated Approval Trial For IFx-2.0 In Advanced Or Metastatic Merkel Cell Carcinoma
09/06/2025 13:40
June 9 (Reuters) - TuHURA Biosciences Inc HURA.O: FDA REMOVES PARTIAL CLINICAL HOLD ON TUHURA BIOSCIENCES' PHASE 3 ACCELERATED APPROVAL TRIAL FOR IFX-2.0 IN ADVANCED OR METASTATIC MERKEL CELL CARCINOMA Source text: ID:nPn1WsNpfa Further company coverage: HURA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on TuHURA Biosciences
See all newsBrief: Tuhura Biosciences Receives Key U.S. Patent For Its Groundbreaking Delta Opioid Receptor Antibody Drug Conjugate Technology
TuHURA Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update
TuHURA Biosciences Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.